Levodopa combined with carbidopa is the most effective medication for Parkinson’s disease and has held that position for over 50 years. It reduces motor symptoms by roughly 40% on average when first started, outperforming every other drug class for tremor, stiffness, and slowness of movement. But “best” depends on your age, your stage of disease, and which symptoms you’re dealing with. Most people with Parkinson’s will use several medications over time, layering them as the disease progresses.
Why Levodopa Is the Gold Standard
Parkinson’s disease is driven by a shortage of dopamine in the brain. The obvious fix would be to take dopamine directly, but dopamine can’t cross from the bloodstream into the brain. Levodopa can. Once it reaches the brain, it’s converted into dopamine inside nerve cells, restoring levels closer to normal and improving movement symptoms.
The problem is that your body also converts levodopa into dopamine outside the brain, in the bloodstream and gut, before it ever reaches where it’s needed. That’s why levodopa is always paired with carbidopa (or a similar companion drug called benserazide in some countries). Carbidopa blocks that premature conversion in the body but can’t enter the brain itself, so more levodopa gets through to do its job.
More than 80% of people with Parkinson’s are diagnosed after age 60, and for this group, levodopa is the clear first choice. The dose should be adjusted based on how well your symptoms respond, not held artificially low. The goal is keeping you active and engaged in daily life.
When Dopamine Agonists Are Used Instead
Dopamine agonists mimic dopamine in the brain rather than supplying the raw material for it. They’re less effective than levodopa for motor symptoms, but they play an important role for younger patients. People diagnosed before age 40 face a greater than 95% chance of developing involuntary movements (dyskinesia) and unpredictable symptom fluctuations after five years on levodopa. Starting with a dopamine agonist can delay that timeline.
For people diagnosed after age 60, those risks are much lower: about 26% chance of dyskinesia after five years for those between 60 and 70, dropping to 16% after age 70. That’s why neurologists are more cautious about dopamine agonists in older patients. These drugs carry their own side effects, including impulse control problems like compulsive gambling, excessive shopping, or hypersexuality, along with daytime sleepiness and swelling in the legs.
MAO-B Inhibitors for Early or Mild Symptoms
If your movement symptoms are still mild, a MAO-B inhibitor may be enough on its own. These drugs slow the breakdown of whatever dopamine your brain still produces naturally, stretching your existing supply further. Rasagiline and selegiline are the most commonly prescribed options in this class. Selegiline can also delay the point at which you need to start levodopa, which matters because levodopa tends to work less predictably over many years of use.
Later in the disease, MAO-B inhibitors shift from solo duty to a supporting role. Added on top of levodopa, they help smooth out the “wearing off” periods that happen when a dose of levodopa starts fading before your next one is due. Safinamide, a newer option in this class, is used specifically as an add-on to levodopa for this purpose.
COMT Inhibitors Extend Each Levodopa Dose
Your body breaks down levodopa through several pathways. When carbidopa blocks one pathway, the body compensates by pushing more levodopa through another, managed by an enzyme called COMT. COMT inhibitors block that second pathway, meaning each dose of levodopa lasts longer and delivers more consistent blood levels. This translates to fewer “off” periods where your symptoms break through.
Entacapone is the older option, taken with each levodopa dose. Opicapone, a newer alternative, inhibits COMT activity for a full 24 hours, so you take it just once daily. These drugs are only used alongside levodopa, never alone.
Rescue Medications for Sudden Off Periods
Even with a well-tuned medication schedule, many people experience sudden episodes where their symptoms return unexpectedly between doses. Three FDA-approved “rescue” options can get you back to functioning within minutes rather than waiting for your next scheduled pill to kick in.
- Subcutaneous apomorphine injection: A self-administered shot under the skin, similar to an insulin pen. Apomorphine is a potent dopamine agonist that absorbs rapidly, providing relief in about 10 to 20 minutes.
- Sublingual apomorphine: A dissolvable film strip placed under the tongue for absorption through the mouth lining, avoiding the need for a needle.
- Inhaled levodopa: A specially designed micropowder inhaler that delivers levodopa through the lungs, bypassing the slow absorption of the gut.
These aren’t replacements for your regular regimen. They’re meant for breakthrough episodes, used a few times a day at most.
Managing Side Effects That Develop Over Time
After about six years on levodopa, roughly half of all patients develop dyskinesia, the involuntary writhing or jerking movements that are a hallmark complication of long-term treatment. In younger patients, the rate reaches nearly 100%. The medication that helps most with dyskinesia is amantadine, which works by a completely different mechanism than other Parkinson’s drugs. It calms overactive signaling at certain receptors in the brain, reducing involuntary movements without making Parkinson’s symptoms worse.
Hallucinations and delusions are another complication that can emerge, particularly later in the disease. Up to half of people with Parkinson’s experience psychosis at some point, often as a side effect of the dopamine-boosting medications themselves. The first step is usually reducing the dose of Parkinson’s medications if possible. When that’s not enough, pimavanserin is the only antipsychotic specifically approved for Parkinson’s disease psychosis. It targets the receptors involved in hallucinations without blocking dopamine, so it doesn’t worsen movement symptoms the way most older antipsychotics would.
Newer Delivery Methods
In August 2024, the FDA approved a longer-acting levodopa/carbidopa pill designed to provide more stable symptom control with fewer daily doses. Two other approaches under development involve continuous delivery of medication through small pumps worn under the skin, similar to insulin pumps. One delivers levodopa/carbidopa and the other delivers apomorphine around the clock, aiming to eliminate the peaks and valleys in drug levels that cause fluctuations. Both received requests from the FDA for additional information about the devices and manufacturing before approval can move forward.
How Treatment Decisions Are Made
Your age at diagnosis, the severity of your symptoms, and your tolerance for specific side effects are the three factors that matter most. For most people over 60 with noticeable motor symptoms, levodopa/carbidopa is the starting point. For younger patients, a dopamine agonist or MAO-B inhibitor may come first, with levodopa added later. As the disease advances, treatment typically becomes a combination: levodopa at the core, with COMT inhibitors or MAO-B inhibitors layered on to extend its effects, amantadine if dyskinesia develops, and rescue medications for unpredictable off periods.
There’s no single “best” medication that works for everyone at every stage. But levodopa remains the most powerful tool available, and for the majority of people with Parkinson’s, it’s both the first and most important part of treatment.